Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure

Autor: Joseph J Cuthbert, Pierpaolo Pellicori, Johannes Petutschnigg, Franco Cosmi, Blerim Mujaj, João Pedro Ferreira, Fozia Z Ahmed, Nicolas Girerd, Faiez Zannad, Roberto Latini, Timothy Collier, Patrick Rossignol, Beatrice Mariottoni, Jan A. Staessen, John G.F. Cleland, Stephane Heymans, Andrew L. Clark, Job A J Verdonschot, Arantxa González, Hans-Peter Brunner-La Rocca
Přispěvatelé: Cardiologie, MUMC+: MA Med Staf Spec Cardiologie (9), RS: Carim - H02 Cardiomyopathy, Robertson Institute of Biostatistics and Clinical Trials Unit, University of Glasgow, Centre d'investigation clinique plurithématique Pierre Drouin [Nancy] (CIC-P), Centre d'investigation clinique [Nancy] (CIC), Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM), Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy] (INI-CRCT), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy], French-Clinical Research Infrastructure Network - F-CRIN [Paris] (Cardiovascular & Renal Clinical Trialists - CRCT ), Cortona Hospital, Department of Cardiology, Maastricht University Medical Center, Manchester Heart Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Sciences Centre, London School of Hygiene and Tropical Medicine (LSHTM), Castle Hill Hospital, Hull York Medical School, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], DZHK (German Center of Cardiovascular Research), Partner Site Berlin, Research Unit Hypertension and Cardiovascular Epidemiology [Louvain, Belgique], Studies Coordinating Centre [Louvain, Belgique], Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven)-Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), Center for Applied Medical Research [Plamplona] (CIMA), Universidad de Navarra [Pamplona] (UNAV), Queensland University of Technology [Brisbane] (QUT), Maastricht University [Maastricht], Cardiovascular Research Institute [Maastricht], Maastricht University Medical Centre - MUMC [Maastricht, The Netherlands], IRCCS - Istituto di Ricerche Farmacologiche 'Mario Negri' [Milan, Italy], Dutch Heart Foundation, CVON2016-Early HFPEF, 2015-10, CVON She-PREDICTS, grant 2017-21, Contrat de plan Etat-lorraine and FEDER lorraine, British Heart Foundation Centre of Research Excellence grant number RE/18/6/34217, ERA-Net-CVD project MacroERA, 01KL1706, IMPACT GEENAGE, ANR-15-IDEX-0004,LUE,Isite LUE(2015), ANR-15-RHUS-0004,FIGHT-HF,Combattre l'insuffisance cardiaque(2015), European Project: 305507,EC:FP7:HEALTH,FP7-HEALTH-2012-INNOVATION-1,HOMAGE(2013), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), DE CARVALHO, Philippe, ISITE - Isite LUE - - LUE2015 - ANR-15-IDEX-0004 - IDEX - VALID, Combattre l'insuffisance cardiaque - - FIGHT-HF2015 - ANR-15-RHUS-0004 - RHUS - VALID, Heart OMics in AGEing - HOMAGE - - EC:FP7:HEALTH2013-02-01 - 2019-01-31 - 305507 - VALID
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Male
Aging
[SDV]Life Sciences [q-bio]
ALDOSTERONE ANTAGONISM
030204 cardiovascular system & hematology
Spironolactone
Ventricular Function
Left
Coronary artery disease
chemistry.chemical_compound
DOUBLE-BLIND
0302 clinical medicine
Interquartile range
Natriuretic Peptide
Brain
Clinical endpoint
Natriuretic peptide
Prospective Studies
COLLAGEN TURNOVER
Ejection fraction
[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology
Atrial fibrillation
DIASTOLIC DYSFUNCTION
3. Good health
[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system
[SDV] Life Sciences [q-bio]
PRESERVED EJECTION FRACTION
BRAIN NATRIURETIC PEPTIDE
Cardiology
Female
Cardiology and Cardiovascular Medicine
medicine.medical_specialty
NT-PROBNP
EXTRACELLULAR-MATRIX TURNOVER
medicine.drug_class
BIOMARKERS
03 medical and health sciences
[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system
Internal medicine
medicine
Humans
Aged
Heart Failure
business.industry
Stroke Volume
Study design
medicine.disease
Fibrosis
Peptide Fragments
Diabetes Mellitus
Type 2
chemistry
HOMAGE
MYOCARDIAL-INFARCTION
Heart failure
business
[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Zdroj: European journal of heart failure, 22(9), 1711-1723. Wiley
European Journal of Heart Failure
European Journal of Heart Failure, Oxford University Press (OUP), 2020, 22 (7), pp.1711-1723. ⟨10.1002/ejhf.1716⟩
European Journal of Heart Failure, 2020, 22 (7), pp.1711-1723. ⟨10.1002/ejhf.1716⟩
ISSN: 1388-9842
DOI: 10.1002/ejhf.1716
Popis: International audience; AIMS:Asymptomatic patients with coronary artery disease (CAD), hypertension and/or type 2 diabetes mellitus (T2DM) are at greater risk of developing heart failure (HF). Fibrosis, leading to myocardial and vascular dysfunction, might be an important pathway of progression. The Heart OMics in AGing (HOMAGE) trial aims to investigate the effects of spironolactone on serum markers of collagen metabolism and on cardiovascular structure and function in people at risk of developing HF and potential interactions with a marker of fibrogenic activity, galectin-3.METHODS AND RESULTS:The HOMAGE trial is a prospective, randomised, open-label, blinded endpoint (PROBE) study comparing spironolactone (up to 50 mg/day) and standard care over 9 months in people with clinical risk factors for developing HF, including hypertension, CAD and T2DM, and elevated plasma concentrations of N-terminal pro-B-type natriuretic peptide (NT-proBNP, 125 to 1000 ng/L) or B-type natriuretic peptide (BNP, 35 to 280 ng/L). Exclusion criteria included left ventricular ejection fraction
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje